Regeneron
AI overview
Sign in and the AI will write an overview from our coverage.
Headlines · 1
- Drug executives challenge near-term AI disease-cure predictions
TechNews, citing The Wall Street Journal, reports that Anthropic CEO Dario Amodei has predicted AI could cure most human diseases within ten years, but executives from Vertex Pharmaceuticals, AstraZeneca, and Regeneron dispute near-term claims of sweeping cures or sharply shortened drug-development timelines. Vertex CEO Jeff Leiden said about 50 AI companies failed to produce a usable drug when given data on thousands of its compounds, while McKinsey senior partner Alex Devereson said current models cannot reliably predict the safety problems behind roughly one-quarter of mid-to-late-stage development failures. McKinsey data cited by TechNews shows $8.4 billion in global venture-capital and private-equity investment in AI drug development during 2025, although only a small number of AI-native biotechnology companies reached late-stage trials and none of their drugs had FDA approval.
科技新报 · 🔥 0
Experience and discussion from the community
Share my Regeneron experienceAsk about Regeneron
Nobody has shared their experience with Regeneron yet.